Filing Flows › Bioventus (BVS) › Q3 2026 › vs Q3 2025
Bioventus (BVS) Q3 2026 vs Q3 2025 (year over year)
Bioventus's revenue rose $3.8M (+3%) from $139M in Q3 2025 to $142M in Q3 2026. Gross margin 68.2% against 68.0% (+0.2 pts).
Bioventus, Q3 2026: revenue $142M (+3% year over year), operating margin 6.8%, net earnings $6.0M, operating cash flow $20.7M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Gross margin | 68.2% | 68.0% | +0.2 pts |
| Operating margin | 6.8% | 8.1% | -1.3 pts |
| Net margin | 4.2% | 2.3% | +1.9 pts |
| Free cash flow margin | 14.3% | 21.4% | -7.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $142M | $139M | $3.8M | +3% |
| Gross profit | $97.1M | $94.2M | $2.9M | +3% |
| Cost of revenue | $45.3M | $44.4M | $892K | +2% |
| Operating profit | $9.7M | $11.3M | −$1.6M | -14% |
| Operating expenses | $87.4M | $83.0M | $4.5M | +5% |
| Pre-tax earnings | $6.2M | $4.7M | $1.5M | +32% |
| Other expense, net | $3.5M | $6.6M | −$3.0M | -46% |
| Research & development | $3.4M | $2.9M | $512K | +18% |
| SG&A | $82.9M | $78.7M | $4.3M | +5% |
| Other operating costs | $1.0M | $1.4M | −$349K | -25% |
| Income tax benefit | $701K | −$664K | $1.4M | — |
| Net earnings | $6.0M | $3.2M | $2.8M | +90% |
| Minority interests | $872K | $851K | $21K | +2% |
| Depreciation & amortization | $10.3M | $11.4M | −$1.1M | -10% |
| Share-based compensation | $4.8M | $3.2M | $1.6M | +50% |
| Working capital & other | $400K | −$12.4M | $12.8M | — |
| Operating cash flow | $20.7M | $30.1M | −$9.4M | -31% |
| Free cash flow (OCF − capex) | $20.3M | $29.6M | −$9.3M | -31% |
| Capital expenditures | $334K | $473K | −$139K | -29% |
Questions
How much did Bioventus's revenue grow year over year in Q3 2026?
Bioventus's revenue rose $3.8M (+3%) from $139M in Q3 2025 to $142M in Q3 2026. Gross margin 68.2% against 68.0% (+0.2 pts).